The 8 most recent market catalysts affecting $LSTA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 15, 2026
Corporate Catalyst
Bearish
Impact 90
Lisata Therapeutics Reports Third Quarter 2026 Financial Results
Lisata Therapeutics announced its third-quarter 2026 financial results, revealing zero revenue for the period, consistent with the prior year. The most critical development is the …
Nov 11, 2026
Corporate Catalyst
Bullish
Impact 85
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Reports Positive Phase 2b TYDAL-TIMI 78 Trial Results
Marea Therapeutics, a subsidiary of Lisata Therapeutics, reported positive Part A results from its Phase 2b TYDAL-TIMI 78 trial for MAR001. The drug demonstrated a significant redu…
Oct 5, 2026
Corporate Catalyst
Bullish
Impact 65
Lisata’s Marea Therapeutics Announces First Patient Dosed In Its Phase 2 Clinical Trial Of MAR002 For Treatment Of Acromegaly
Lisata Therapeutics, through its subsidiary Marea Therapeutics, has initiated a Phase 2 clinical trial for MAR002, an investigational therapy for acromegaly. This is a crucial mile…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 95
Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy
Lisata Therapeutics (LSTA) has undergone a transformative event by acquiring Marea Therapeutics, gaining a new pipeline of cardioendocrine therapeutics. This acquisition is fully f…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 75
Lisata Therapeutics shares are trading higher after the company announced it acquired Marea Therapeutics.
This headline signals a positive corporate catalyst for Lisata Therapeutics. Acquisitions often lead to increased investor confidence due to potential synergies, pipeline expansion…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 95
Lisata Therapeutics Announces Suit Against Kuva Labs Seeking Damages And $2M Termination Fee; Cuts Approximately 72% Of Full-Time Employees
Lisata Therapeutics' 8-K filing reveals a significant corporate upheaval. The company is suing Kuva Labs for breaching their merger agreement, indicating a failed acquisition that …
Jul 24, 2026
Corporate Catalyst
Bearish
Impact 85
Lisata Therapeutics shares are trading lower after the company announced it has terminated its merger agreement with Kuva Labs.
The termination of a merger agreement is a significant corporate catalyst, especially for the acquiring or target company. For Lisata Therapeutics (LSTA), this news is overwhelming…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.